BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging(TM) Technology Holds Potential Across Multiple Endoscopic Procedures

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is focused on changing the standards of visualizing cancer during minimally invasive procedures. The company’s innovative technology has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System is based on advanced optics and light sensors and uses patented ultrasensitive imaging technology. The state-of-the-art control unit features a dual-wavelength light source, two-channel camera control and data recorder. Simultaneous white and blue light illumination of the bladder allows for side-to-side image monitoring and better visualization of tumors and margins. A recent article discussing this reads, “The primary focus of Imagin Medical’s i/Blue Imaging(TM) System is bladder cancer, the sixth most prevalent type of cancer in the United States with one of the highest recurrence rates. The technology has the potential for use in other minimally invasive procedures, with plans already in motion to implement this system for multiple endoscopic procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast dye agents and illumination sources.”

To view the full article, visit https://ibn.fm/QBJwv

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork